Cartesian Growth (GLBL) Shareholders Approve Tiedemann Group and Alvarium Investments Deal
by Marlena Haddad on 2022-11-17 at 3:09pm

Cartesian Growth Corporation (NASDAQ:GLBL) announced this afternoon that its shareholders have approved its business combination with wealth management firms Tiedemann Group and Alvarium Investments during a special meeting held earlier today.

The SPAC did not disclose redemption amounts, but the share price of GLBL briefly spiked to a high of $28.49 yesterday on volume of 1,183,779 shares. GLBL’s share price has since come down and is currently trading today near $10.27.

Additionally, Cartesian stated that the closing-related processes are “underway, but in the interest of merger-accounting simplicity, the closing will not occur until January 3, 2023, after the end of the 2022 fiscal year.” However, there was no explanation as to why there is a potential six-week delay to close this combination. Plus, whether the redemptions will happen in 2022 or would happen concurrently with the closing in 2023, which would subject it to the 1% excise tax.

Upon closing, the combined company will operate as Alvarium Tiedemann Holdings and its common stock and warrants are expected to be listed on Nasdaq under the ticker symbols “GLBL” and “GLBLW”, respectively.

The parties initially announced their $1 billion combination on September 20, 2021. The two firms serve as alternative asset managers to clients on four continents and are expected to have about $60 billion in assets under management by the end of 2021.


ADVISORS

  • Piper Sandler & Co. is serving as financial advisor to the Tiedemann Group.
  • Seward & Kissel LLP is serving as legal counsel to the Tiedemann Group.
  • The Asset & Wealth Management Investment Banking Group of Raymond James & Associates, Inc. and Spencer House Partners LLP are serving as financial advisors to Alvarium.
  • Goodwin Procter LLP is serving as legal counsel to Alvarium.
  • Cantor Fitzgerald & Co. is serving as capital markets advisor to Cartesian Growth Corporation.
  • BofA Securities is serving as financial advisor and capital markets advisor to Cartesian.
  • Greenberg Traurig, LLP is serving as legal counsel to Cartesian.
Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved